Opportunities and challenges for the clinical translation of structured DNA assemblies as gene therapeutic delivery and vaccine vectors.

Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology
Marina A Dobrovolskaia, Mark Bathe

Abstract

Gene therapeutics including siRNAs, anti-sense oligos, messenger RNAs, and CRISPR ribonucleoprotein complexes offer unmet potential to treat over 7,000 known genetic diseases, as well as cancer, through targeted in vivo modulation of aberrant gene expression and immune cell activation. Compared with viral vectors, nonviral delivery vectors offer controlled immunogenicity and low manufacturing cost, yet suffer from limitations in toxicity, targeting, and transduction efficiency. Structured DNA assemblies fabricated using the principle of scaffolded DNA origami offer a new nonviral delivery vector with intrinsic, yet controllable immunostimulatory properties and virus-like spatial presentation of ligands and immunogens for cell-specific targeting, activation, and control over intracellular trafficking, in addition to low manufacturing cost. However, the relative utilities and limitations of these vectors must clearly be demonstrated in preclinical studies for their clinical potential to be realized. Here, we review the major capabilities, opportunities, and challenges we foresee in translating these next-generation delivery and vaccine vectors to the clinic. This article is categorized under: Therapeutic Approaches and Drug Disco...Continue Reading

References

Apr 25, 1997·Biochemical Pharmacology·D R ShawS Agrawal
Nov 15, 1997·Antisense & Nucleic Acid Drug Development·S P HenryD J Kornbrust
Nov 15, 1997·Antisense & Nucleic Acid Drug Development·S P HenryD J Kornbrust
Jun 6, 1998·Science·M U KoppA Manz
Jun 15, 1999·Toxicologic Pathology·D K Monteith, A A Levin
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J NemunaitisS G Eckhardt
Apr 28, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J S WatersF E Cotter
May 8, 2001·Immunologic Research·D S Pisetsky
Jul 12, 2001·Antisense & Nucleic Acid Drug Development·M S WebbD J Kornbrust
Mar 17, 2006·Nature·Paul W K Rothemund
Nov 8, 2006·Nucleic Acids Research·L ChasteenA R M Bradbury
Jul 5, 2007·Nature Reviews. Molecular Cell Biology·Satyajit Mayor, Richard E Pagano
Jul 21, 2007·International Journal of Pharmaceutics·Haruna SakuraiHiroyuki Mizuguchi
Oct 25, 2008·Nature Reviews. Cancer·Yaron MosessonYosef Yarden
Apr 1, 2009·Nano Letters·Asmaa ElbakryMiriam Breunig
Sep 10, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Marc T AbramsLaura Sepp-Lorenzino
Feb 4, 2010·Cell Research·Sudha KumariSatyajit Mayor
Apr 14, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Stephan T SternScott E McNeil
May 1, 2010·Cancer Research·Takemi TanakaMauro Ferrari
Aug 25, 2010·International Journal of Pharmaceutics·Walter E Rudzinski, Tejraj M Aminabhavi
Jan 27, 2011·Cancer Immunology, Immunotherapy : CII·Elizabeth A VasievichLeaf Huang
Mar 2, 2011·Nature Methods·Carlos Ernesto CastroHendrik Dietz
May 10, 2011·Science Progress·Igor Pantic
Nov 19, 2011·ACS Nano·Verena J SchüllerTim Liedl
Dec 24, 2011·Nanomedicine·Diana BoraschiPaola Italiani
Feb 22, 2012·Science·Shawn M DouglasGeorge M Church
Mar 13, 2012·The AAPS Journal·Neil Desai
Apr 13, 2012·Journal of Virology·Michael A DiMattiaMavis Agbandje-McKenna
Apr 21, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Eugene MahonKenneth A Dawson
Jun 5, 2012·Nature Nanotechnology·Hyukjin LeeDaniel G Anderson
Jun 12, 2012·Nanomedicine : Nanotechnology, Biology, and Medicine·Michael L EtheridgeJeffrey McCullough

❮ Previous
Next ❯

Citations

Jan 31, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Yelixza I AvilaMarina A Dobrovolskaia
May 20, 2021·Nucleic Acids Research·Erik PoppletonPetr Šulc
Jun 19, 2021·Nature Communications·Shih-Ting WangOleg Gang
Jun 26, 2021·Nanomedicine·Martin PanigajKirill A Afonin

❮ Previous
Next ❯

Methods Mentioned

BETA
antisense oligonucleotide
antisense oligonucleotides

Software Mentioned

TALOS
DAEDALUS

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Related Papers

Chemical Reviews
Meredith A Mintzer, Eric E Simanek
Accounts of Chemical Research
Xia Guo, Leaf Huang
Ernst Schering Research Foundation Workshop
J A Wolff, H Herweijer
Current Drug Delivery
Anjuman A BegumPeter M Moyle
© 2021 Meta ULC. All rights reserved